Skip to main content

Table 2 Factors associated with vanB VRE bacteraemia

From: Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia

Factors associated with vanBVRE bacteraemia

VRE cases (n = 116)

Controls (n = 116)

Univariable

Multivariable

OR

95% CI

p-value

OR

95% CI

p-value

Age, median (IQR), years

60 (47–68)

58 (44–68)

1.01

0.99-1.02

0.481

   

Female

47 (41)

53 (46)

0.81

0.48-1.36

0.432

   

Transfer from another hospital

28 (24)

14 (12)

2.56

1.18-5.52

0.017

   

Unit of admission

        

  Non-haematology/oncology to read Non-haematology/oncology

55 (47)

49 (42)

Reference

   

  Haematology/

oncology

61 (53)

67 (58)

0

-

-

   

ICU admission in prior 30 days

39 (34)

13 (11)

6.57

2.97-14.55

<0.001

   

CDS-VRE score, median (IQR)

1 (0–1.9)

0 (0–1.6)

1.36

1.02-1.80

0.036

1.70

1.05-2.77

0.032

Clostridium difficile toxin positive

5 (4)

1 (1)

5.00

0.58-42.80

0.142

   

Infection(s) due to pathogens other than Enterococci

61 (53)

34 (29)

2.93

1.60-5.37

0.001

0.97

0.39-2.46

0.953

Gastrointestinal disease

54 (47)

38 (33)

2.00

1.10-3.64

0.024

   

Liver disease

16 (14)

15 (13)

1.14

0.41-3.15

0.796

   

Haematological malignancy

66 (57)

63 (54)

1.6

0.52-4.89

0.410

0.41

0.06-2.61

0.342

Bone marrow transplantation type

  Nil

97 (84)

100 (86)

Reference

Reference

  Autologous

3 (3)

7 (6)

0.33

0.07-1.65

0.178

0.27

0.03-2.22

0.221

  Allogeneic

16 (14)

9 (8)

2.40

0.85-6.81

0.100

2.79

0.57-13.66

0.206

Ceftriaxone days, median (IQR), days

0 (0)

0 (0)

1.09

0.98-1.22

0.130

1.16

0.91-1.48

0.234

Third generation cephalosporin days , median (IQR), daysa

0 (0–1)

0 (0–0.49)

1.04

0.95-1.13

0.439

   

Fluoroquinolone days, median (IQR), daysb

1 (0–7.63)

0 (0–2.42)

1.07

1.01-1.12

0.016

   

Metronidazole days, median (IQR), days

0 (0–1.78)

0 (0)

1.54

1.16-2.04

0.003

1.65

1.17-2.33

0.004

Ticarcillin-clavulanic acid days, median (IQR), days

0 (0)

0 (0)

1.02

0.92-1.13

0.674

   

Piperacillin-tazobactam days, median (IQR), days

0 (0–2.18)

0 (0)

1.04

0.96-1.14

0.352

   

Meropenem days, median (IQR), days

0 (0–5.94)

0 (0)

1.15

1.06-1.25

0.001

   

Vancomycin days, median (IQR), days

2.58 (0–8)

0 (0–2.18)

1.10

1.04-1.17

0.002

1.04

0.95-1.15

0.401

Neutropenia days, median (IQR), days

1 (0–10)

0 (0–1)

1.08

1.03-1.14

0.003

1.04

0.96-1.11

0.341

Hypoalbuminaemia days, median (IQR), days

13 (7.5-20)

5.5 (2–14.5)

1.08

1.04-1.12

<0.001

0.97

0.91-1.04

0.435

Central line use

94 (81)

55 (47)

5.22

2.56-10.66

<0.001

3.06

0.94-9.99

0.063

Mechanical ventilation

29 (25)

7 (6)

5.40

2.08-14.02

0.001

   

Urinary catheter

57 (49)

27 (23)

3.50

1.84-6.65

<0.001

2.86

1.09-7.53

0.033

Parenteral nutrition

28 (24)

8 (7)

3.86

1.68-8.86

0.001

   
  1. Note:
  2. Data are number (%) of patients unless indicated otherwise.
  3. aThird generation cephalosporins include cefotaxime, ceftriaxone, and ceftazidime.
  4. bFluoroquinolones include moxifloxacin, norfloxacin and ciprofloxacin.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us